All In Biotech

Drug Trial Radar · NCT07040787

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

A Single-center, Single-arm, Fixed-sequence Drug-drug Interaction Study of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jul 8, 2025

Primary completion

Aug 17, 2025

Study completion Aug 17, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to compare the drug-drug interaction of HRS-5965 with clopidogrel and clarithromycin in healthy subjects.

Conditions

  • Complement Mediated Glomerular Diseases
  • Hemolytic Anemia

Interventions

  • HRS-5965 CapsulesDrug

    Oral HRS-5965 capsules.

  • ClopidogrelDrug

    Oral clopidogrel.

  • ClarithromycinDrug

    Oral clarithromycin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximum plasma concentration (Cmax)Time frame: Day 1 to day 12.
  2. Area under the concentration curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 to day 12.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.